Scythian Biosciences Corp. appoints Peter Liabotis as chief financial officer.

by • September 28, 2018 • Appointment, Feature Slider, Feature-Home, Featured-Slides-HomeComments Off on Scythian Biosciences Corp. appoints Peter Liabotis as chief financial officer.73

Scythian Biosciences Corp. appoints Peter Liabotis, a veteran senior corporate finance executive and certified public accountant, as chief financial officer. He will be replacing Jonathan Held who will be stepping down from his current position of chief financial officer. 

Liabotis has 20+ years of experience includes serving as a chief financial officer with both U.S. and Canadian public companies across several industries.

“Peter brings expertise in complex financial issues to Scythian as we embark on building out a portfolio of blue-chip cannabis companies across the United States,” says Scythian CEO Rob Reid. “He is an accomplished financial strategist with exceptional analytical and transactional skills who communicates effectively with stock exchanges, regulators, bankers and other key stakeholders. Peter is the perfect complement to the existing management team as we push forward to execute our aggressive business plan.”

Prior to joining Scythian, Liabotis was chief financial officer of a publicly-traded Toronto merchant bank which invested in equity, debt and convertible debt in early and growth-stage public and private companies.

Additionally, he also served in senior finance executive roles with four junior mining Canadian and U.S. public companies. Prior to that, he was financial controller for a private wealth manager, and group chief financial officer/senior vice president of a global offshore hedge-fund administrator. Peter started his career in public accounting working for both PricewaterhouseCoopers in Bermuda and KPMG in Canada.

Liabotis is a chartered professional accountant and holds a Bachelor of Commerce degree from the University of Windsor, Ontario, and a Bachelor of Arts degree from Western University in London, Ontario.

Scythian Biosciences also granted him 255,000 stock options pursuant to the company’s stock option plan and 11,765 deferred share units pursuant to the deferred share unit plan. Each stock option is exercisable for one common share in the capital of the company at an exercise price of $4.25 per share for a period of five years from the grant date. One third of the stock options will vest immediately upon the grant date, an additional one third will vest upon the first anniversary of the grant date and the remaining one third will vest upon the second anniversary of the grant date.

Comments are closed.